Trial Profile
A randomised, double-blind, placebo-controlled trial assessing the efficacy and safety of dutasteride (Avodart) 0.5 mg in extending the time to PSA [prostate specific antigen] doubling in men with prostate cancer and biochemical failure (PSA increase) after radical therapy with curative intent (ARTS-Avodart After Radical Therapy for Prostate Cancer Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Dutasteride (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms ARTS
- Sponsors GlaxoSmithKline
- 01 May 2013 Primary endpoint 'Prostate-specific-antigen-doubling-time' has been met.
- 12 May 2012 This trial is recruiting in France, Spain and has been discontinued in Lithuania, Latvia.
- 09 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.